BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 38680498)

  • 1. CAR-based immunotherapy for breast cancer: peculiarities, ongoing investigations, and future strategies.
    Niu Z; Wu J; Zhao Q; Zhang J; Zhang P; Yang Y
    Front Immunol; 2024; 15():1385571. PubMed ID: 38680498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimeric antigen receptor-natural killer cell therapy: current advancements and strategies to overcome challenges.
    Kong JC; Sa'ad MA; Vijayan HM; Ravichandran M; Balakrishnan V; Tham SK; Tye GJ
    Front Immunol; 2024; 15():1384039. PubMed ID: 38726000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effective adoptive immunotherapy of triple-negative breast cancer by folate receptor-alpha redirected CAR T cells is influenced by surface antigen expression level.
    Song DG; Ye Q; Poussin M; Chacon JA; Figini M; Powell DJ
    J Hematol Oncol; 2016 Jul; 9(1):56. PubMed ID: 27439908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Challenges and strategies in relation to effective CAR-T cell immunotherapy for solid tumors.
    Yuan G; Ye M; Zhang Y; Zeng X
    Med Oncol; 2024 Apr; 41(5):126. PubMed ID: 38652178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CAR-macrophage versus CAR-T for solid tumors: The race between a rising star and a superstar.
    Chen K; Liu ML; Wang JC; Fang S
    Biomol Biomed; 2024 May; 24(3):465-476. PubMed ID: 37877819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current Advancements in Anti-Cancer Chimeric Antigen Receptor T Cell Immunotherapy and How Nanotechnology May Change the Game.
    Ku KS; Tang J; Chen Y; Shi Y
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new era of cancer immunotherapy: combining revolutionary technologies for enhanced CAR-M therapy.
    Li N; Geng S; Dong ZZ; Jin Y; Ying H; Li HW; Shi L
    Mol Cancer; 2024 Jun; 23(1):117. PubMed ID: 38824567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting TRIM29 As a Negative Regulator of CAR-NK Cell Effector Function to Improve Antitumor Efficacy of these Cells: A Perspective.
    Saleh Z; Noroozi M; Vakili ME; Kabelitz D; Nasrollahi H; Kalantar K
    Curr Mol Med; 2024; 24(4):399-403. PubMed ID: 37218209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new vision of the efficacy of both CAR-NK and CAR-T cells in treating cancers and autoimmune diseases.
    Hassan SH; Alshahrani MY; Saleh RO; Mohammed BA; Kumar A; Almalki SG; Alkhafaji AT; Ghildiyal P; Al-Tameemi AR; Elawady A
    Med Oncol; 2024 Apr; 41(6):127. PubMed ID: 38656354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer.
    Byrd TT; Fousek K; Pignata A; Szot C; Samaha H; Seaman S; Dobrolecki L; Salsman VS; Oo HZ; Bielamowicz K; Landi D; Rainusso N; Hicks J; Powell S; Baker ML; Wels WS; Koch J; Sorensen PH; Deneen B; Ellis MJ; Lewis MT; Hegde M; Fletcher BS; St Croix B; Ahmed N
    Cancer Res; 2018 Jan; 78(2):489-500. PubMed ID: 29183891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficient combination of radiotherapy and CAR-T - A systematic review.
    Szlasa W; Sztuder A; Kaczmar-Dybko A; Maciejczyk A; Dybko J
    Biomed Pharmacother; 2024 May; 174():116532. PubMed ID: 38574625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Newer generations of multi-target CAR and STAb-T immunotherapeutics: NEXT CART Consortium as a cooperative effort to overcome current limitations.
    Martín-Antonio B; Blanco B; González-Murillo Á; Hidalgo L; Minguillón J; Pérez-Chacón G;
    Front Immunol; 2024; 15():1386856. PubMed ID: 38779672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CAR T therapy from haematological malignancies to aging-related diseases: An ever-expanding universe.
    Ramoni D; Montecucco F; Carbone F
    Eur J Clin Invest; 2024 Jul; 54(7):e14203. PubMed ID: 38551245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The enchanting canvas of CAR technology: Unveiling its wonders in non-neoplastic diseases.
    Shu J; Xie W; Chen Z; Offringa R; Hu Y; Mei H
    Med; 2024 Jun; 5(6):495-529. PubMed ID: 38608709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The involvement and application potential of exosomes in breast cancer immunotherapy.
    Wang Y; Ma Q; Wang T; Xing J; Li Q; Wang D; Wang G
    Front Immunol; 2024; 15():1384946. PubMed ID: 38835784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanoparticle-Mediated Immunotherapy in Triple-Negative Breast Cancer.
    Wang R; Huang X; Chen X; Zhang Y
    ACS Biomater Sci Eng; 2024 Jun; 10(6):3568-3598. PubMed ID: 38815129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Tumor Immune Microenvironment in Breast Cancer Progression.
    Otterlei Fjørtoft M; Huse K; Rye IH
    Acta Oncol; 2024 May; 63():359-367. PubMed ID: 38779867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NK-92 cells labeled with Fe
    Lian J; Li M; Duan M; Sun Y; Wang Z; Guo X; Li J; Gao G; Li K
    J Nanobiotechnology; 2024 Jun; 22(1):313. PubMed ID: 38840120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CAR-T therapy for ovarian cancer: Recent advances and future directions.
    Xin Q; Chen Y; Sun X; Li R; Wu Y; Huang X
    Biochem Pharmacol; 2024 Jun; 226():116349. PubMed ID: 38852648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting metabolism of breast cancer and its implications in T cell immunotherapy.
    Zou J; Mai C; Lin Z; Zhou J; Lai G
    Front Immunol; 2024; 15():1381970. PubMed ID: 38680483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.